Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of liposomal irinotecan + S-1 versus liposomal irinotecan + 5-fluorouracil/leucovorin in metastatic pancreatic cancer after gemcitabine failure
NL-OMON55645Phase 2Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Dec 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PC) comparing Liposomal irinotecan + S-1 with Liposomal irinotecan + fluorouracil + leucovorin (2 arms). Primary endpoints: Dose-limiting toxicity, Maximum tolerated dose and 1 more. Started Dec 2019; status: recruiting.
02
Drugs
nanoliposomal irinotecantegafurfluorouracilfolinic acid
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PC)
Beyond the preview
Go deeper on NL-OMON55645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55645.